SEARCH:   Advanced

Blood, 15 January 2009, Vol. 113, No. 3, pp. 535-537. Prepublished online as a Blood First Edition Paper on November 13, 2008; DOI 10.1182/blood-2008-08-173450. This Article Full Text (PDF) All Versions of this Article: blood-2008-08-173450v1 113/3/535    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Awan, F. T Articles by Lucas, D. M Search for Related Content PubMed PubMed Citation Articles by Awan, F. T Articles by Lucas, D. M Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted August 13, 2008 Accepted November 1, 2008 Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab Farrukh T Awan, Neil E Kay, Melanie E Davis, Wenting Wu, Susan M Geyer, Nelson Leung, Diane F Jelinek, Renee C Tschumper, Charla R Secreto, Thomas S Lin, Michael R Grever, Tait D Shanafelt, Clive S Zent, Timothy G Call, Nyla A Heerema, Gerard Lozanski, John C Byrd, and David M Lucas* Ohio State University, Columbus, OH, United States Mayo Clinic, Rochester, MN, United States * Corresponding author; email: david.lucas{at}osumc.edu. Myeloid cell factor-1 (Mcl-1) is an anti-apoptotic member of the Bcl-2 protein family. Increased Mcl-1 expression is associated with failure to achieve remission after treatment with fludarabine and chlorambucil in patients with chronic lymphocytic leukemia (CLL). However, the influence of Mcl-1 expression has not been examined in CLL trials using chemoimmunotherapy. We investigated Mcl-1 protein expression prospectively as part of a Phase II study evaluating the efficacy of pentostatin, cyclophosphamide and rituximab in patients with untreated CLL. No significant difference by Mcl-1 expression was noted in pre-treatment or response parameters. However in patients with higher Mcl-1 expression, both minimal residual disease-negative status and progression-free survival was found to be significantly reduced (57% vs. 19%, p=0.01; 50.8 vs. 18.7 months; p=0.02; respectively). Mcl-1 expression may therefore be useful in predicting poor response to chemoimmunotherapy. These findings further support pursuing treatment strategies targeting this important anti-apoptotic protein. Because the trials described were conducted before the requirement to register them was implemented, they are not registered in a clinical trial database. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. Enzler, A. P. Kater, W. Zhang, G. F. Widhopf II, H.-Y. Chuang, J. Lee, E. Avery, C. M. Croce, M. Karin, and T. J. Kipps Chronic lymphocytic leukemia of E{micro}-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression Blood, November 12, 2009; 114(20): 4469 - 4476. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020